Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension.

White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, Chang W, Keefe DL.

J Clin Hypertens (Greenwich). 2010 Oct;12(10):765-75. doi: 10.1111/j.1751-7176.2010.00352.x.

2.
3.

Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.

Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL.

Hypertens Res. 2009 Mar;32(3):169-75. doi: 10.1038/hr.2008.21. Epub 2009 Jan 23.

PMID:
19262478
4.

Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions.

Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Garofoli M, Ramundo E, Biadetti A, Verdecchia P.

Curr Drug Saf. 2012 Feb;7(1):76-85. Review.

PMID:
22663961
5.
6.

Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.

Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J.

Curr Med Res Opin. 2008 Apr;24(4):1039-47. doi: 10.1185/030079908X280581 . Epub 2008 Feb 27.

PMID:
18307835
7.

Renin inhibition in hypertension.

Gradman AH, Kad R.

J Am Coll Cardiol. 2008 Feb 5;51(5):519-28. doi: 10.1016/j.jacc.2007.10.027. Review.

8.

Renin inhibitors.

Fisher ND, Meagher EA.

J Clin Hypertens (Greenwich). 2011 Sep;13(9):662-6. doi: 10.1111/j.1751-7176.2011.00514.x. Epub 2011 Jul 27. Review.

9.

Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients.

White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, Chang W, Keefe DL.

J Clin Hypertens (Greenwich). 2011 Jul;13(7):506-16. doi: 10.1111/j.1751-7176.2011.00438.x. Epub 2011 Mar 18.

10.

Efficacy and safety profile of aliskiren: practical implications for clinicians.

Angeli F, Reboldi G, Poltronieri C, Angeli E, De Filippo V, Crocetti A, Bartolini C, D'Ambrosio C, Verdecchia P.

Curr Drug Saf. 2014;9(2):106-17. Review.

PMID:
24517108
11.

Aliskiren for renin inhibition: a new class of antihypertensives.

Van Tassell BW, Munger MA.

Ann Pharmacother. 2007 Mar;41(3):456-64. Epub 2007 Mar 6. Review.

PMID:
17341529
12.

Blood pressure lowering efficacy of renin inhibitors for primary hypertension.

Musini VM, Fortin PM, Bassett K, Wright JM.

Cochrane Database Syst Rev. 2008 Oct 8;(4):CD007066. doi: 10.1002/14651858.CD007066.pub2. Review. Update in: Cochrane Database Syst Rev. 2017 Apr 05;4:CD007066.

PMID:
18843743
13.

An observational, prospective, open-label, multicentre evaluation of aliskiren in treated, uncontrolled patients: a real-life, long-term, follow-up, clinical practice in Italy.

Tocci G, Aimo G, Caputo D, De Matteis C, Di Napoli T, Granatelli A, Lentini P, Magagna A, Matarrese AA, Perona D, Villa G, Volpe M; DRIVE Investigators.

High Blood Press Cardiovasc Prev. 2012 Jun 1;19(2):73-83. doi: 10.2165/11632170-000000000-00000.

PMID:
22867093
14.

Direct renin inhibition: an evaluation of the safety and tolerability of aliskiren.

Rashid H.

Curr Med Res Opin. 2008 Sep;24(9):2627-37. doi: 10.1185/03007990802336541 . Epub 2008 Aug 6. Review.

PMID:
18687166
15.

Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies.

Gradman AH, Weir MR, Wright M, Bush CA, Keefe DL.

J Hum Hypertens. 2010 Nov;24(11):721-9. doi: 10.1038/jhh.2010.11. Epub 2010 Mar 4.

PMID:
20200550
16.

Aliskiren: the first direct renin inhibitor available for clinical use.

Morganti A, Lonati C.

J Nephrol. 2011 Sep-Oct;24(5):541-9. doi: 10.5301/jn.5000008. Review.

PMID:
21786226
17.
18.
19.

Direct renin inhibitor induced renal failure.

Vallakati A, Chandra PA, Hollander G, Shani J.

Am J Ther. 2014 Mar-Apr;21(2):e53-5. doi: 10.1097/MJT.0b013e3182459c16.

PMID:
23665882
20.

Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.

Buczko W, Hermanowicz JM.

Pharmacol Rep. 2008 Sep-Oct;60(5):623-31. Review.

Supplemental Content

Support Center